Back to Search
Start Over
Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants.
- Source :
-
JCO precision oncology [JCO Precis Oncol] 2021 Nov; Vol. 5, pp. 1677-1686. - Publication Year :
- 2021
-
Abstract
- Purpose: Multigene panel testing (MGPT) identifies TP53 pathogenic or likely pathogenic (P/LP) variants in patients with diverse phenotypes, of which only one is classic Li-Fraumeni syndrome. Low variant allelic fraction (VAF) in TP53 found on germline testing may suggest aberrant clonal expansion or constitutional mosaicism. We evaluated TP53 -positive probands seen in a cancer genetics program to determine germline versus somatic status.<br />Methods: We reviewed TP53 -positive probands from 2012 to 2019 identified by MGPT on blood or saliva (N = 84). Available VAFs were collected. Probands with a familial variant, who met Li-Fraumeni syndrome testing criteria or who carried a founder variant, were considered germline. For those with uncertain germline status, TP53 variants were further examined using ancillary data of family members and somatic tissue.<br />Results: Of the 84 probands, 54.7% had germline variants with 33.3% meeting criteria for germline status and 21.4% confirmed through ancillary testing. Aberrant clonal expansion comprised 13.1% with clonal hematopoiesis of indeterminate potential and 2.4% with a hematologic malignancy. Constitutional mosaicism was confirmed in 8.3% probands. Definitive status could not be determined in 3.6% despite ancillary assessment, and 17.9% did not have ancillary testing.<br />Conclusion: A TP53 P/LP variant found on peripheral blood or saliva MGPT does not always originate in the germline. In a clinical cancer genetics cohort, approximately half of the patients had TP53 P/LP germline variants; these patients plus those with constitutional mosaicism require intensified surveillance. A framework of multiple strategies enables discernment of germline from constitutional mosaic and acquired variants, which is essential for appropriate management.<br />Competing Interests: Alison N. SchwartzConsulting or Advisory Role: InVitae Nadine M. TungResearch Funding: AstraZeneca (Inst) Jeffrey N. WeitzelSpeakers' Bureau: AstraZeneca Huma Q. RanaResearch Funding: Ambry Genetics, InVitae Corp Judy E. GarberConsulting or Advisory Role: Novartis (I), GTx (I), Helix BioPharma, Konica Minolta, Aleta BioTherapeutics (I), H3 Biomedicine (I), Kronos Bio (I)Research Funding: Novartis (I), Ambry Genetics, InVitae, Myriad GeneticsOther Relationship: Susan G. Komen for the Cure (I), AACR, Diana Helis Henry Medical Foundation (I), James P. Wilmot Foundation (I), Adrienne Helis Malvin Medical Research Foundation (I), Breast Cancer Research Foundation, Facing our Risk of Cancer EmpoweredNo other potential conflicts of interest were reported.
- Subjects :
- Adult
Aged
Aged, 80 and over
Female
Genetic Testing
Genetic Variation
Germ Cells
Humans
Male
Middle Aged
Retrospective Studies
Tumor Suppressor Protein p53 blood
Young Adult
Li-Fraumeni Syndrome blood
Li-Fraumeni Syndrome genetics
Saliva chemistry
Tumor Suppressor Protein p53 analysis
Tumor Suppressor Protein p53 genetics
Subjects
Details
- Language :
- English
- ISSN :
- 2473-4284
- Volume :
- 5
- Database :
- MEDLINE
- Journal :
- JCO precision oncology
- Publication Type :
- Academic Journal
- Accession number :
- 34994652
- Full Text :
- https://doi.org/10.1200/PO.21.00278